BMS Presents Results of Mavacamten in (EXPLORER-LTE) Cohort of the (MAVA-LTE) Study for Symptomatic Obstructive Hypertrophic Cardiomyopathy at ACC 2022
Shots:
- The (EXPLORER-LTE) cohort of the (MAVA-LTE) study evaluates mavacamten (5mg, qd) vs PBO in a ratio (1:1) in 251 patients with symptomatic obstructive HCM for 30wks. Additionally, 200 patients remained in the study for 48+ wks., & 67 patients had reached 84wks.
- The interim analysis showed 94% patients remained on mavacamten, improvement in LVOT gradients, NYHA class & NT-proBNP levels @48 & 84wks., 67.5% & 60.2% improved by ≥1 NYHA & 1 NYHA classes from baseline with 7.3% by 2 NYHA classes @48wks. the safety results were consistent with (EXPLORER-HCM) study with no new safety signals
- Additionally, 10 (4.3%) permanently discontinued due to TEAEs & 26 (11%) discontinuing temporarily for any reason and resuming treatment thereafter
Ref: Businesswire | Image: BMS
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
